This clinical trial is focused on studying advanced solid cancers, which include various types such as squamous cell carcinoma of the head and neck, non-small cell lung cancer, cutaneous melanoma, triple-negative breast cancer, renal cell carcinoma, urothelial carcinoma, and cancers of the stomach, esophagus, cervix, and colon. The study is investigating a new treatment called BMS-986288, which is being tested both on its own and in combination with another medication called Nivolumab. Additionally, the study will compare the combination of BMS-986288 and Nivolumab with a medication called Regorafenib in certain cases of colon cancer.
The purpose of this study is to understand the safety and tolerability of BMS-986288, as well as to find the best dose to use when given alone or with Nivolumab. The study will also look at how effective the combination of BMS-986288 and Nivolumab is compared to Regorafenib in treating colon cancer. Participants in the study will receive the treatments through either an injection or as tablets, depending on the medication being tested. The study will monitor participants for any side effects and how well the cancer responds to the treatment.
This trial is divided into different parts, with each part focusing on specific goals. In the initial phases, the study will focus on determining the safest dose of BMS-986288. Later phases will compare the effectiveness of the combination treatment against Regorafenib. Participants will be closely monitored throughout the study to ensure their safety and to gather information on how the treatments affect their cancer. The study aims to provide valuable insights into new treatment options for people with advanced solid cancers.



France
Italy
Spain